TY - JOUR
T1 - Orbital atherectomy for the treatment of severely calcified coronary lesions
T2 - evidence, technique, and best practices
AU - Shlofmitz, Evan
AU - Martinsen, Brad J.
AU - Lee, Michael
AU - Rao, Sunil V.
AU - Généreux, Philippe
AU - Higgins, Joe
AU - Chambers, Jeffrey W.
AU - Kirtane, Ajay J.
AU - Brilakis, Emmanouil S.
AU - Kandzari, David E.
AU - Sharma, Samin K.
AU - Shlofmitz, Richard
N1 - Funding Information:
E Shlofmitz has a consulting agreement with Cardiovascular Systems, Inc. BJ Martinsen is an employee of Cardiovascular Systems, Inc. M Lee has a consulting agreement with Cardiovascular Systems, Inc. SV Rao has a consulting agreement with Cardiovascular Systems, Inc. P Généreux has a consulting agreement with Cardiovascular Systems, Inc. J Higgins is an employee of Cardiovascular Systems, Inc. JW Chambers has a consulting agreement with Cardiovascular Systems, Inc. AJ Kirtane reports institutional grants to Columbia University and/or Cardiovascular Research Foundation from Medtronic, Boston Scientific, Abbott Vascular, Abiomed, CSI, CathWorks, Siemens, Philips, ReCor Medical, Spectranetics. ES Brilakis has a consulting agreement with Cardiovascular Systems, Inc. consulting/speaker honoraria from Abbott Vascular, Amgen, Asahi, Elsevier, GE Healthcare, and Medicure; research support from Boston Scientific and Osprey; spouse is employee of Medtronic. DE Kandzari reports personal consulting honoraria: Biotronik, Boston Scientific, Medtronic, Micell Technologies; Institutional research/educational grant support: Abbott/St. Jude, Cardiovascular Systems, Biotronik, Boston Scientific, Orbus Neich, Medtronic, Micell Technologies. SK Sharma has a consulting agreement with Cardiovascular Systems, Inc. R Shlofmitz has a consulting agreement with Cardiovascular Systems, Inc. Writing assistance was utilized in the preparation of this manuscript, it was funded by Cardiovascular Systems, Inc and carried out by Nick Hargus, Ph.D.; Cardiovascular Systems, Inc and Ann Behrens, B.S.; Cardiovascular Systems, Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.
Publisher Copyright:
© 2017 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2017/11/2
Y1 - 2017/11/2
N2 - Introduction: The presence of severe coronary artery calcification is associated with higher rates of angiographic complications during percutaneous coronary intervention (PCI), as well as higher major adverse cardiac events compared with non-calcified lesions. Incorporating orbital atherectomy (OAS) for effective preparation of severely calcified lesions can help maximize the benefits of PCI by attaining maximal luminal gain (or stent expansion) and improve long-term outcomes (by reducing need for revascularization). Areas covered: In this manuscript, the prevalence, risk factors, and impact of coronary artery calcification on PCI are reviewed. Based on current data and experience, the authors review orbital atherectomy technique and best practices to optimize lesion preparation. Expert Commentary: The coronary OAS is the only device approved for use in the U.S. as a treatment for de novo, severely calcified coronary lesions to facilitate stent delivery. Advantages of the device include its ease of use and a mechanism of action that treats bi-directionally, allowing for continuous blood flow during treatment, minimizing heat damage, slow flow, and subsequent need for revascularization. The OAS technique tips reviewed in this article will help inform interventional cardiologists treating patients with severely calcified lesions.
AB - Introduction: The presence of severe coronary artery calcification is associated with higher rates of angiographic complications during percutaneous coronary intervention (PCI), as well as higher major adverse cardiac events compared with non-calcified lesions. Incorporating orbital atherectomy (OAS) for effective preparation of severely calcified lesions can help maximize the benefits of PCI by attaining maximal luminal gain (or stent expansion) and improve long-term outcomes (by reducing need for revascularization). Areas covered: In this manuscript, the prevalence, risk factors, and impact of coronary artery calcification on PCI are reviewed. Based on current data and experience, the authors review orbital atherectomy technique and best practices to optimize lesion preparation. Expert Commentary: The coronary OAS is the only device approved for use in the U.S. as a treatment for de novo, severely calcified coronary lesions to facilitate stent delivery. Advantages of the device include its ease of use and a mechanism of action that treats bi-directionally, allowing for continuous blood flow during treatment, minimizing heat damage, slow flow, and subsequent need for revascularization. The OAS technique tips reviewed in this article will help inform interventional cardiologists treating patients with severely calcified lesions.
KW - Atherectomy
KW - atherectomy technique
KW - coronary artery calcification
KW - coronary artery disease
KW - orbital atherectomy
KW - percutaneous coronary intervention
KW - stents
UR - http://www.scopus.com/inward/record.url?scp=85032303680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85032303680&partnerID=8YFLogxK
U2 - 10.1080/17434440.2017.1384695
DO - 10.1080/17434440.2017.1384695
M3 - Review article
C2 - 28945162
AN - SCOPUS:85032303680
SN - 1743-4440
VL - 14
SP - 867
EP - 879
JO - Expert Review of Medical Devices
JF - Expert Review of Medical Devices
IS - 11
ER -